Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal Women
SSRI 对围绝经期女性更年期症状的功效
基本信息
- 批准号:8135398
- 负责人:
- 金额:$ 29.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-15 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAfrican AmericanAnxietyBehavioralBostonClinicalClinical TrialsCoronary heart diseaseData Coordinating CenterDementiaDepressed moodDevicesDistressDoseDouble-Blind MethodEnrollmentEscitalopramEstradiolEstrogensFatigueFrequenciesFunctional disorderGoalsGoldHealthcare SystemsHormonalHot flushesImpaired cognitionInterventionLeadLinkMeasuresMenopausal SymptomMenopauseMental DepressionMonitorMoodsNight SweatingPatientsPerimenopausePharmaceutical PreparationsPhiladelphiaPlacebosPopulation HeterogeneityPostmenopausePrincipal InvestigatorProgestinsProtocols documentationPublic HealthQuality of lifeRaceRandomizedRandomized Controlled TrialsReportingResearch PersonnelRiskRoleSafetyScientistSelective Serotonin Reuptake InhibitorSerotoninSerotonin AgentsSeveritiesSiteSleepSleep DisordersSleep disturbancesStagingStressStrokeSweatSweatingSymptomsSystemTestingTherapeuticTimeTreatment EfficacyTreatment ProtocolsVasomotorWomanWomen&aposs HealthWorkalternative treatmentbody-minddiariesdouble-blind placebo controlled trialexperiencehormone therapyimprovedinhibitor/antagonistmalignant breast neoplasmmiddle agemind controlprogramsracial differencerandomized placebo controlled trialreproductiveresponsereuptaketreatment response
项目摘要
DESCRIPTION (provided by applicant): This application proposes a clinical trial within a network of scientists who are highly knowledgeable about the menopausal transition and experienced in the conduct of women's health trials in order to fulfill the main objective of this RFA, which is to accelerate the identification of effective remedies to relieve vasomotor symptoms. This application is submitted in conjunction with the network titled "The Menopausal Symptoms Initiative - Finding Lasting Answers to Sweats and Hot Flashes" (MSI-FLASH). The Data Coordinating Center (DCC) of the network is led by A. LaCroix and G. Anderson, who have served as Co-Principal Investigators of the Women's Health, Initiative, Clinical Coordinating Center (Seattle) for more than a decade. The MSI-FLASH network has 5 clinical field sites located in Boston (L. Cohen and H. Jaffe, PIs), Indianapolis (J Carpenter, PI),Oakland, CA (B Sternfeld and B Caan, PIs),Philadelphia (E. Freeman, PI) and Seattle (K Newton and S Reed, PIs). This multi disciplinary investigator group proposes 5 randomized controlled trials that test a range of behavioral, mind-body, hormonal and pharmacologic interventions for menopausal hot flashes. This field site proposes a randomized, placebo-controlled trial to determine the efficacy of a serotonergic reuptake inhibitor (SSRI) for reducing hot flashes associated with menopause and determine the effects of known covariates of hot flashes in treatment response. The specific aims are to 1) Determine the efficacy of the SSRI escitalopram compared with placebo in reducing the frequency, severity and bothersomeness of hot flashes; 2) Determine associations of baseline measures of anxiety, depressed mood, poor sleep, perceived stress, menopausal stage and race with improvement of hot flashes; 3) Determine whether changes in anxiety and depressed mood during treatment are associated with decreases in hot flashes with escitalopram compared to placebo; 4) Determine the time course for improvement of hot flashes with escitalopram compared to placebo. Approximately 180 women will be randomized to double-blind treatment, and enrollment will be stratified to obtain equal numbers of African American and white women. It is expected that 3 other field sites of the Network will also conduct this protocol, providing a collaborative and multi disciplinary approach, diverse populations and a rapid completion of the treatment protocol. Increased information about treatment efficacy and the factors associated with treatment response, including whether there are racial differences in response to treatment, will lead to better therapeutic strategies for women who experience distressing and disruptive menopausal symptoms. Information about responses to a serotonergic treatment may increase understanding of associations between hot flashes and the serotonergic system.
描述(由申请人提供):本申请提出在科学家网络中进行临床试验,这些科学家对绝经过渡期有很高的了解,并在进行女性健康试验方面有丰富的经验,以实现本RFA的主要目标,即加速确定缓解血管痉挛症状的有效补救措施。本申请与题为“月经症状倡议-寻找持久的答案出汗和潮热”(MSI-FLASH)的网络一起提交。该网络的数据协调中心(DCC)由A。LaCroix和G.安德森,谁担任联合首席研究员的妇女健康,倡议,临床协调中心(西雅图)超过十年。MSI-FLASH网络在波士顿(L。Cohen和H.贾菲,PI),印第安纳波利斯(J卡彭特,PI),奥克兰,加利福尼亚州(B斯特恩菲尔德和B凯恩,PI),费城(E。弗里曼,PI)和西雅图(K牛顿和S里德,PI)。这个多学科研究小组提出了5项随机对照试验,测试了一系列行为,身心,激素和药物干预更年期潮热。该现场网站提出了一项随机、安慰剂对照试验,以确定β-肾上腺素能再摄取抑制剂(SSRI)减少更年期相关潮热的疗效,并确定潮热的已知协变量对治疗反应的影响。具体目的是:1)确定SSRI艾司西酞普兰与安慰剂相比在减少潮热的频率、严重程度和困扰方面的疗效; 2)确定焦虑、抑郁情绪、睡眠不良、感知压力、绝经阶段和种族的基线测量与潮热改善的相关性; 3)确定治疗期间焦虑和抑郁情绪的变化是否与艾司西酞普兰与安慰剂相比减少潮热有关; 4)确定艾司西酞普兰与安慰剂相比改善潮热的时间过程。约180名女性将随机接受双盲治疗,并对入组进行分层,以获得相同数量的非裔美国人和白色女性。预计该网络的其他3个外地地点也将执行这一方案,提供一种协作和多学科的办法,使人口多样化,并迅速完成治疗方案。增加关于治疗疗效和与治疗反应相关的因素的信息,包括治疗反应是否存在种族差异,将为经历痛苦和破坏性更年期症状的女性提供更好的治疗策略。关于对肾上腺素能治疗的反应的信息可以增加对潮热和肾上腺素能系统之间的关联的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELLEN W FREEMAN其他文献
ELLEN W FREEMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELLEN W FREEMAN', 18)}}的其他基金
Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal Women
SSRI 对围绝经期女性更年期症状的功效
- 批准号:
7533564 - 财政年份:2008
- 资助金额:
$ 29.98万 - 项目类别:
Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal Women
SSRI 对围绝经期女性更年期症状的功效
- 批准号:
7923832 - 财政年份:2008
- 资助金额:
$ 29.98万 - 项目类别:
Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal Women
SSRI 对围绝经期女性更年期症状的功效
- 批准号:
8312529 - 财政年份:2008
- 资助金额:
$ 29.98万 - 项目类别:
Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal Women
SSRI 对围绝经期女性更年期症状的功效
- 批准号:
7682127 - 财政年份:2008
- 资助金额:
$ 29.98万 - 项目类别:
Core symptoms and profiles in premenstrual syndrome
经前综合症的核心症状和概况
- 批准号:
7319434 - 财政年份:2007
- 资助金额:
$ 29.98万 - 项目类别:
Core symptoms and profiles in premenstrual syndrome
经前综合症的核心症状和概况
- 批准号:
7489355 - 财政年份:2007
- 资助金额:
$ 29.98万 - 项目类别:
CAREER DEVELOPMENT IN WOMEN'S HEALTH RESEARCH AND GENDE*
女性健康研究和性别领域的职业发展*
- 批准号:
6949089 - 财政年份:2002
- 资助金额:
$ 29.98万 - 项目类别:
CAREER DEVELOPMENT IN WOMEN'S HEALTH RESEARCH AND GENDE*
女性健康研究和性别领域的职业发展*
- 批准号:
7103649 - 财政年份:2002
- 资助金额:
$ 29.98万 - 项目类别:
EPIDEMIOLOGY STUDY OF THE LATE REPRODUCTIVE YEARS
生育后期的流行病学研究
- 批准号:
6565771 - 财政年份:2001
- 资助金额:
$ 29.98万 - 项目类别:
EPIDEMIOLOGY STUDY OF THE LATE REPRODUCTIVE YEARS
生育后期的流行病学研究
- 批准号:
6468021 - 财政年份:2000
- 资助金额:
$ 29.98万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 29.98万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 29.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 29.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 29.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 29.98万 - 项目类别:
Discovery Grants Program - Individual